The Week

Alnylam Pharma (ALNY) fell 3.67% for the week to $239.56, trailing the S&P 500 by around 3.59 percentage points. The week was choppy. Monday opened at $250.165 and touched $252.79 before fading; Tuesday saw the heaviest selling, with volume rising to 2.175m shares as the stock dipped to $237.44. Wednesday marked the low at $236, Thursday rebounded to $245.51, and Friday slipped back to $239.56. Weekly amplitude was 6.71%, and average daily volume of 1.56m shares ran about 7.9% above the median.

Key Events

The week’s focus was on fresh RNAi data and the longer-term Zilebesiran story. On Monday, commentary asked whether ALNY was 33% undervalued after the data release. Tuesday’s piece noted the sell-off looked ugly, but Wall Street still saw a much brighter picture. On Friday, two items centred on Zilebesiran: one highlighted twice-yearly dosing for continuous hypertension control with strong phase III momentum, and another repeated a buy rating with a $357 price target based on the long-term Zilebesiran opportunity. The company-specific thread this week was the pipeline rather than any new financial or regulatory news.

Analyst Ratings

Coverage totals 29 institutions: 16 rate it buy, 6 overweight, 7 hold, and none underweight or sell. The consensus rating is buy, with a consensus target of $371.35, about 55% above the week’s close. Targets range from $256 to $536, pointing to a wide spread. Within the biotech industry, ALNY ranks 5th, ahead of the industry mean and median coverage levels.

The Week Ahead

No company-specific earnings are on the calendar. The focus shifts to macro data: Richmond Fed composite index on Tuesday, EIA weekly crude and Cushing inventories on Wednesday, and jobless claims, current account, new home sales, and EIA natural gas storage on Thursday. If risk appetite reacts to macro readings, biotech valuations may feel the effect through the week.

In Short

The tension this week is clear: ALNY underperformed the market on the week, and the latest session’s flows showed large-lot money turning net seller. Yet the consensus rating remains buy, the consensus target sits more than half above spot, and almost all covering institutions rate it buy or overweight. What comes next is whether pipeline data momentum and macro sentiment can support the current valuation.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.